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Obesity has become a major worldwide challenge to public health, due to the Western
‘obesogenic’ environment interacting with a strong genetic contribution1. Recent extensive
genome-wide association studies (GWAS) have identified numerous single nucleotide
polymorphisms (SNPs) associated with obesity, but these loci together account for only a
small fraction of the known heritable component1. Thus, the “common disease, common
variant” paradigm is increasingly under challenge2. We report a highly-penetrant form of
obesity, initially observed in 31 subjects who were heterozygous for deletions of at least
593kb at 16p11.2 and whose ascertainment included cognitive deficits. Nineteen similar
deletions were identified from GWAS data in 16053 individuals from 8 European cohorts.
Such deletions were absent from healthy non-obese controls and accounted for 0.7% of our
morbid obesity cases (body mass index, BMI ≥ 40 kg.m−2 or BMI standard deviation score
≥ 4; p = 6.4×10−8, OR = 43.0), demonstrating the potential importance in common disease
of rare variants with strong effects. This highlights a promising strategy for identifying
missing heritability in obesity and other complex traits: Cohorts with extreme phenotypes
are likely to be enriched for rare variants, thereby improving power for their discovery.
Subsequent analysis of the loci so identified may well reveal additional rare variants that
further contribute to the missing heritability, as recently reported for SIM13. Thus, the most
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productive approach may be to combine the “power of the extreme”4 in small, well-
phenotyped cohorts, with targeted follow-up in GWAS and population cohorts.
The extent to which copy number variants (CNVs) might contribute to the missing
heritability of common disorders is currently much under debate2. Since the majority of
common simple CNVs are well-tagged by SNPs, it has recently been suggested that
common CNVs are unlikely to contribute substantially to the missing heritability5.
However, rare variants or recurring CNVs that have arisen on multiple independent
occasions are unlikely to be captured by SNP tagging, and their identification will require
alternative approaches.
We have previously hypothesised that cohorts with extreme phenotypes that include obesity
may be enriched for rare but very potent risk variants4,6. Here we have investigated 312
subjects, from three centres in the UK and France, presenting with congenital malformations
and/or developmental delay in addition to obesity as previously defined6,7 (see Methods).
Known syndromes (e.g. Prader-Willi, fragile X etc.) were excluded. A combination of array
comparative genomic hybridisation (aCGH), genotyping arrays, quantitative PCR (qPCR)
and multiplex ligation-dependent probe amplification (MLPA) was used to identify and
confirm the presence of a heterozygous deletion on 16p11.2 in 9 individuals (2.9%). Such
deletions, estimated to be a total of 740kb in size (one copy of a segmental duplication plus
593kb of unique sequences, Figure 1a), have previously been associated to varying extents
with autism, schizophrenia and developmental delay8-11; however, the observed frequency
of deletions in our cohort is appreciably higher than the reported frequencies in the cohorts
from the previous studies (<1%), which did not include obesity as an inclusion criterion.
A parallel, independent survey of aCGH and SNP-CGH data from 8 cytogenetic centres in
France, Switzerland and Estonia, of 3,947 patients with developmental delay and/or
malformations, but this time without selection for obesity, revealed 22 unrelated cases with
similar deletions (0.6%). This is a frequency consistent with the previous studies8-11, but is
significantly lower than for the above cohort which included only obese subjects
(p=2.2×10−4, Fisher’s exact test).
Analysis of the available clinical data for these 22 new carriers indicated that, in addition to
the ascertained cognitive deficits or behavioural abnormalities (including hyperphagia,
specifically identified in at least 9 cases; see Supplementary Table S1), a 16p11.2 deletion
gave rise to a strongly-expressed obesity phenotype in adults, with a more variable
phenotype in childhood. All 4 teenagers and adults carrying a deletion were obese, while
child carriers were also frequently either obese (4/15) or overweight (2/15), a tendency that
has previously been noted11; the very young (under 2 years) were of normal weight. This
age-dependent penetrance was observed for all instances of deletions where phenotypic data
were available, whether from this study or from previously published reports10-15, and
regardless of ascertainment (Figure 2; see Supplementary Tables S2 and S3).
Taken together, the data from these parallel studies suggest a possible direct association of
deletions at 16p11.2 with obesity, distinct from their cognitive phenotype. Also identified in
these cohorts were instances of the reciprocal duplication, which has also been implicated in
neurodevelopmental disorders, but with a variable phenotype and lower penetrance9,10,12.
The frequency of the duplication in the two cohorts (12/4183, 0.3%) was consistent with
previous reports for patients with cognitive deficits (0.3–0.7%)10,12. Carriers of the
duplication were neither obese nor had reported hyperphagia.
To further investigate the association of 16p11.2 deletions with obesity, and to estimate the
extent to which it is observed independently of ascertainment for neurodevelopmental
symptoms, we carried out algorithmic and statistical analyses of genome-wide SNP
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genotyping data (see Table 1) from Swiss (CoLaus16), Finnish (NFBC6617) and Estonian
(EGPUT18) general population cohorts (11,856 subjects in total), from child obesity and
adult morbid obesity case-control cohorts6,19,20 (1,224 and 1,548 subjects respectively),
from an extreme early-onset obesity cohort (SCOOP, 931 subjects) and from 141 patients
undergoing bariatric weight-loss surgery (see online Methods); in total, we identified 17
instances of deletions (and 4 duplications) with no significant gender bias (Table 1). In
addition, we identified 2 further unrelated carriers of a deletion from amongst 353 members
of 149 families with sibling pairs discordant for obesity (SOS Sib Pair Study21). Where
DNA was available for further analysis (15/19 samples), the presence of a deletion was
validated using MLPA (Figure 1b) or qPCR; the remaining deletions were validated by
applying a second independent algorithm to the data. With the exception of a single
individual who is apparently diabetic (fasting glucose > 7 mmol/L), all adult carriers of such
deletions were obese, the majority being morbidly obese; similarly, each of the 7 child/
adolescent carriers had a BMI in the top 0.1% of the population range for their age and
gender. None of the individuals ascertained on the basis of their obesity had any reported
developmental delay or cognitive deficit; four subjects were reported as having hyperphagia.
To enable sufficient statistical power to give robust conclusions, we combined data from the
population and obesity cohorts in an overall case-control association analysis (the samples
from sib pair families were excluded to avoid complications due to their relatedness).
Compared to lean/normal weight subjects (see Table 1 and Methods), 16p11.2 deletions
were associated with obesity (p = 5.7×10−7, Fisher’s exact test; odds ratio = 29.8, 95%
confidence limits = 4.0, 225) and morbid obesity (p = 6.4×10−8; OR = 43.0 [5.6, 329]) at or
near genome-wide levels of significance. Expanding the control group to include all non-
obese individuals increased the significance to p = 4.1×10−9 (obese) and p = 6.1×10−10
(morbidly obese).
Previous reports have indicated that these deletions are frequently not inherited from either
parent but arises de novo, possibly by non-allelic homologous recombination between the
>99% sequence identical segmental duplications flanking the deleted region11,14.
Therefore, where possible we investigated the parents of carriers of deletions, identifying 11
cases of maternal transmission and 4 of paternal transmission. The available data showed
that all first-degree relatives carrying a deletion were also obese (Supplementary Table S1).
In 10 instances the deletion was apparently de novo (see Figure 1b). Extrapolation to our full
dataset indicates that ~0.4% of all morbidly obese cases are due to an inherited 16p11.2
deletion. The frequency of de novo events is consistent with the previous report where
ascertainment was for developmental delay and/or congenital anomalies11; by contrast,
deletions are reported to be almost exclusively de novo in autistic subjects8-10.
Although they may be heterogeneous in nature, these deletions are highly likely to be the
causal variants, representing the second most frequent genetic cause of obesity after point
mutations in MC4R22,23. Their repeated de novo occurrence is likely to result in lack of
linkage disequilibrium with any other flanking variant – no consistent haplotype has been
identified by analysis of the available surrounding genotypes. To assess the effect of a
deletion on the expression of nearby genes (e.g. the obesity GWAS-associated SH2B1 locus
800kb away24), we analysed available transcript data for subcutaneous adipose tissue
samples from the discordant sibling cohort. Comparisons of the 2 subjects carrying a
deletion with their corresponding non-obese siblings, and with other obese and non-obese
subjects (Supplementary Figure S4 and Supplementary Tables S4 and S5), showed that
many though not all transcripts from within the deletion had markedly reduced abundance
(0.4-0.7 fold). In contrast, no clear evidence was found for consistent cis effects of the
deletion on the abundance of mRNAs encoded by genes flanking the deletion. In addition,
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global analysis of this dataset has not identified any trans expression quantitative trait loci
either within or nearby the deletion.
Thus, while we cannot completely exclude that a 16p11.2 deletion affects the expression of
nearby genes (for instance, its impact may be different in other tissues), the above
expression analysis strongly indicates that the observed phenotypes are likely to be due to
haploinsufficiency of one or more of the ~30 genes within the deleted region. Indeed, rather
than being due to a single haploinsufficiency, the phenotype may well result from the
deletion of multiple genes that impact on pathways central to the development of obesity
(see Supplementary Table S5). Functional network analysis of the deleted genes has led to
the suggestion of a similar multi-gene effect for the cognitive phenotype8. The extent to
which there is overlap between the genes involved in the obesity and cognitive phenotypes
remains to be elucidated.
There is a strong correlation between developmental and cognitive disabilities and the
prevalence of obesity: Patients with autism or who have learning disabilities have a greatly
increased risk of obesity25; and the severely obese exhibit significant cognitive
impairment26. Possible explanations include a direct causal relationship between obesity
and developmental delay; the involvement of the same or related regulatory pathways; or
different outcomes of the same set of behavioural disorders with complex pleiotropic effects
and variable ages of onset and expressivities. The higher frequency of 16p11.2 deletions in
the cohort ascertained for both phenotypes (2.9%), compared to cohorts ascertained for
either phenotype alone (0.4%, 0.6% respectively), confirms their impact on both obesity and
developmental delay, adding to the evidence that these two phenotypes may be
fundamentally interrelated.
Methods Summary
Obesity
Definitions for overweight, obesity and morbid obesity were based on previous studies6,7:
for adults, BMI ≥ 25, 30 and 40 kg.m−2 respectively; for children, BMI respectively above
the 90th, 97th percentiles and ≥ 4 standard deviations above the mean, calculated according
to their age and gender from a French reference population27,28.
Statistics
All reported statistical tests used Fisher’s exact test29, carried out on contingency tables
constructed for the number of subjects carrying/lacking a 16p11.2 deletion versus the
obesity status/ascertainment of the individual. Since no homozygous deletions were
observed, it was unnecessary to make a prior distinction between recessive, additive and
dominant models of disease risk. Odds ratios and 95% confidence limits were calculated as
described30.
CNV discovery
Subjects ascertained for cognitive deficit/malformations with or without obesity were
selected from those clinically referred for genetic testing; 16p11.2 deletions were identified
in these individuals by standard clinical diagnostic procedures. Algorithmic analyses of
GWAS data were variously carried out using the cnvHap algorithm; a moving window
average intensity procedure; a Gaussian Mixture Model; QuantiSNP; PennCNV; BeadStudio
GT module; and Birdseed. Where experimental validation was not possible, at least two
independent algorithms were used for each dataset.
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Online Methods
Obesity phenotype
We have used previously-defined criteria for to define overweight, obesity and morbid (class
III) obesity6,7; in adults, the thresholds were BMI ≥ 25, 30 and 40 kg.m−2 respectively. In
children and adolescents, we used age- and sex-specific percentiles of BMI, calculated from
a French reference population27,28, that approximately correspond to these thresholds:
overweight and obesity were defined by thresholds at the 90th and 97th percentiles
respectively. Childhood morbid obesity was defined as BMI ≥ 4 SDs above the age- and
sex-specific mean, which corresponds to a BMI of 40 kg.m−2 between the ages of 20 and 30
years for both men and women; this threshold was used in the recruitment of the SCOOP
severe early-onset obesity cohorts7. The age- and sex-specific thresholds use to define
obesity and morbid obesity are shown in Figure 1 and Supplementary Figures 1-2. No
carriers of a 16p11.2 deletion were reported to be taking atypical antipsychotics (known to
be associated with weight gain).
Patient and population cohorts
Patients referred for cognitive delay and obesity—A group of 33 patients was
selected from those referred for genetic testing at the North West Thames Regional Genetics
Service, based at Northwick Park Hospital in Harrow, UK, with approval from the Harrow
Research Ethics Committee. Inclusion was based on 3 criteria: mental retardation;
dysmorphology; and weight >97th percentile for age and gender. Abnormal karyotype,
Fragile X and Prader Willi Syndrome were previously excluded.
A second group of 279 French children were selected from those referred to 2 centres
(Laboratoire de Diagnostic Génétique, Nouvel Hôpital Civil, Strasbourg; Centre de
Génétique Chromosomique, Hôpital Saint-Vincent de Paul, GHICL, Lille). Inclusion was
based on obesity plus at least one Prader Willi-like syndromic feature (neonatal hypotonia
and difficulty to thrive, mental retardation, developmental delay, behavioural problems, skin
picking, facial dysmorphism, hypogenitalism or hypogonadism). Chromosomal
abnormalities and Prader Willi Syndrome were excluded by karyotyping and DNA
methylation analysis.
Patients referred for cognitive delay—Patients with cognitive deficits are routinely
referred to clinical genetics for etiological work-ups including aCGH. We surveyed 7
cytogenetic centres in France and Switzerland, identifying 3870 patients ascertained for
developmental delay and/or malformations. Also included in the study were a further 77
patients, ascertained on similar criteria, who were referred to the Department of Genetics,
University of Tartu. These analyses were performed for clinical diagnostic purposes, all
available phenotypic data (weight, height) being those provided anonymously by the
clinician ordering the analysis. Consequently, research-based informed consent was not
required by the institutional review board that approved the study.
CoLaus—This prospective population cohort was described previously16: 6188 white
individuals aged 35–75 years were randomly selected from the general population in
Lausanne, Switzerland. These individuals underwent a detailed phenotypic assessment, and
were genotyped using the Affymetrix Mapping 500K array; 5612 samples passed
genotyping quality control. This study was approved by the institutional review boards of
the University of Lausanne, and written consent was obtained from all participants. Because
recruitment of this cohort required the ability to give informed consent, it is possible that the
(statistically non-significant) lack of 16p11.2 deletions/duplications is due to an
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ascertainment bias. However, any such bias, if it exists, is very small and affects the
identification of only 1-2 subjects carrying a deletion.
NFBC1966—The Northern Finland Birth Cohort 1966 is a prospective birth cohort of
almost all individuals born in 1966 in the two northernmost provinces of Finland. Expectant
mothers were enrolled and clinical data collection took place prenatally, at birth, and at ages
six months, one year, 14 years and 31 years. Biochemical and DNA samples were collected
with informed consent at age 31 years. Genotyping using the Illumina Infinium 370cnvDuo
array and phenotypic characteristics of the cohort were as previously described17.
Phenotypic and genotyping data was available for 5246 subjects after quality control.
EGPUT—The Estonian Genome Project is a biobank coordinated by the University of
Tartu (EGPUT)18. The project is conducted according to Estonian Gene Research Act and
all participants have given written informed consent. The cohort includes more than 39000
individuals older than 18 years of age and reflects closely the age distribution in the
Estonian population (33% male, 67% female; 83% Estonians, 14% Russians, 3% other).
Subjects are recruited by general practitioners (GP) and hospital physicians and are then
randomly selected. Computer Assisted Personal interview (CAPI) was filled during 1-2
hours at the doctor’s office. The data included personal data (place of birth, place(s) of
living, nationality etc.), family history (four generations), educational and occupational
history, lifestyle and anthropometric data. 1090 randomly-selected subjects were genotyped
using the Illumina 370cnvDuo array, 998 passing the required criteria (nationality,
genotyping call rate, phenotype availability).
Case-Control familial obesity—The adult-obesity case-control groups and the child-
obesity case control groups were as previously published6, and were genotyped using the
Illumina Human CNV370-duo array. 643 children with familial obesity (BMI ≥ 97th
percentile corrected for gender and age, at least one obese first degree relative, age < 18 yr),
581 non-obese children (BMI ≤ 90th percentile), 705 morbidly obese adults with familial
obesity (BMI ≥ 40 kg/m2, at least one obese first degree relative with BMI ≥ 35 kg/m2, age
≥ 18 yr) and 197 lean adults (BMI ≤ 25 kg/m2) passed quality control; this cohort included a
further 646 control subjects from the DESIR prospective cohort19 (age at exam ≥ 45 yr,
normal fasting glucose according to 1997 ADA criteria, BMI < 27 kg/m2) genotyped using
the Illumina Hap300 array20. All participants or their legal guardians gave written informed
consent, and all local ethics committees approved the study protocol.
Severe early-onset obesity cohort—The Genetics of Obesity Study (GOOS) cohort
consists of over 3000 patients ascertained for severe obesity, defined as a BMI ≥ 4 SDs
above the age- and sex-specific mean, and onset of obesity before 10 years of age. In this
study, we selected a discovery set of 1000 UK Caucasian patients from this cohort in whom
developmental delay had been excluded by routine clinical examination by experienced
Physicians (this cohort is referred to as SCOOP). Mutations in LEPR, POMC and MC4R
were excluded by direct nucleotide sequencing and a karyotype was performed. DNA
samples were analysed using Affymetrix Genome-Wide Human SNP Array 6.0 by Aros, Inc
(Århus, Denmark), of which 931 passed quality control.
Bariatric surgery cohort—Patients undergoing elective bariatric weight-loss surgery for
were recruited for the ABOS study at Lille Regional University Hospital. Genotyping was
carried out using the Illumina Human 1M-duo array, and data from 141 adults passed quality
control. All participants gave written informed consent, and the study protocol was approved
by the local ethics committee.
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Swedish discordant sibling cohort—The SOS Sib Pair Study cohort was as previously
published21. It includes 154 nuclear families, each with BMI discordant sibling pairs (BMI
difference >10 kg.m−2), giving a total of 732 subjects. Genotyping data using the Illumina
610K-Quad array was available for 353 siblings from 149 families. Expression data from
subcutaneous adipose tissue (sampled after overnight fasting) were available for 360 siblings
from 151 families. Subjects received written and oral information before giving written
informed consent. The Regional Ethics Committee in Gothenburg approved the studies.
Statistical Methods
In view of the low frequency of the 16p11.2 deletions, all reported statistical tests were
carried out using Fisher’s exact test29. This was applied to comparisons of separately-
ascertained cohorts or categories and was carried out on contingency tables constructed for
the number of subjects carrying/lacking a 16p11.2 deletion (zero or one copies, as no
homozygous deletions were observed) versus the obesity status/ascertainment of the
individual. Since no homozygous deletions were observed, it was unnecessary to make a
prior distinction between recessive, additive and dominant models of disease risk. For
overall analysis of the obesity risk resulting from a deletion, cohorts were pooled according
to their obesity status determined according to the criteria described above, and the
described tests were then applied to the pooled data. Odds ratios and 95% confidence limits
were calculated as described30.
CNV discovery and validation
Clinical identification of 16p11.2 deletions—All diagnostic procedures (aCGH,
qPCR, QMPSF, FISH) were carried out according to the relevant guidelines of good clinical
laboratory practice for the respective countries. All rearrangements in probands were
confirmed by a second technique and karyotyping was performed in all cases to exclude a
complex rearrangement.
cnvHap—CNVs were detected in the child/adult case-control, bariatric surgery, SOS
sibpair and NFBC cohorts using the cnvHap algorithm (Coin et al., manuscript submitted);
this method is based on an Hidden Markov Model which models transitions between copy
number states at the haplotype level, improving sensitivity and accuracy by capturing LD
information between CNVs and SNPs. The compiled JAR and associated parameter files can
be downloaded from http://www.imperial.ac.uk/medicine/people/l.coin/. Sample data from
the algorithm applied to the NFBC cohort is illustrated in Supplementary Figure S5a.
After clustering of genotyping data using the internal Illumina BeadStudio cluster files,
values for logR ratio (LRR) and B allele frequency (BAF) were exported from each project
and normalised: Effects of %GC content on LRR were removed by regressing on GC and
GC2, while wave effects31 were removed by fitting a loess function. Normalised data for
probes within 2.5Mb of the 16p11.2 deletion were analysed using cnvHap, and CNV calls
intersecting the single-copy sequences within the deletion (chr16:29514353-30107356, build
hg18) were extracted. 16p11.2 deletions were identified by a minimum 90% of probes
within the deleted region being called as having reduced copy number.
All called 16p11.2 deletions were validated by direct analysis of LRR. Data for each probe
were normalised by first subtracting the median value across all samples (so that the
distribution of LRR for each probes was centred on zero), and then dividing by the variance
across all samples (to correct for variation in the sensitivity of different probes to copy
number variation). The normalised data were then smoothed by application of a 9-point
moving average and visualised graphically (see Supplementary Figure S6); putative
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deletions were checked by subsequent manual confirmation of loss-of-heterozygosity across
the entire region. Equally, all deletions called by this method were confirmed by cnvHap.
Gaussian Mixture Model—For the CoLaus cohort, raw genotyping data were normalized
using the aroma.affymetrix framework32. Normalization steps included allelic cross-talk
calibration33,34, intensity summarization using robust median average and correction for
any PCR amplification bias. CN ratios for a given sample, at a given SNP or CN probe,
were computed as the log2 ratio of the normalized intensity of this probe divided by the
median across all the samples. CN ratios were subsequently smoothed by fitting a Loess
function31. CNV calling was done using a new method based on a Gaussian mixture model
(Valsesia et al., manuscript in preparation). This Gaussian mixture model fits four
components (deletion, copy neutral, 1 and 2 additional copy) to CN ratios. The final copy
number at each probe location is determined as the expected (dosage) copy number. The
method has been validated by comparing test datasets with results from the CNAT35 and
CBS36,37 algorithms and by replicating a subset of CoLaus subject on Illumina arrays. All
calls at the 16p11.2 locus made by the highly stringent CBS algorithm were replicated by
the Gaussian mixture model. Principal components analysis detected no significant batch
effects. Sample data from the algorithm applied to the CoLaus cohort is illustrated in
Supplementary Figure S5b.
PennCNV, QuantiSNP and Birdsuite—CNV discovery in the EGPUT cohort was
carried out using QuantiSNP38, PennCNV39 and BeadStudio GT module (Illumina Inc.).
All analyses were carried out using the recommended settings, except changing EMiters to
25 and L to 1,000,000 in QuantiSNP. For PennCNV, the Estonian population-specific B-
allele frequency file was used. Data from the SCOOP cohort were analysed using
Affymetrix Power Tools and Birdsuite software40
Multiplex ligation-dependent probe amplification (MLPA)—MLPA was carried out
according to standard methods41 using reagents obtained from MRC-Holland (Amsterdam
NL). The SALSA MLPA Kit P343-B1 Autism-1 probemix was used, which contained 9
probes within the deleted region on 16p11.2, plus one probe upstream and one downstream
of this locus (see Figure 1a). MLPA products were separated using an AB3130 Genetic
Analyser (Applied Biosystems) and outputs were analysed using GeneMarker software (Soft
Genetics) and Microsoft Excel. Data normalisation was carried out by dividing the peak
areas for each of the 11 test probes by the mean of 9 control probe peak areas. Normalised
peak area data were then compared across the tested samples to determine which ones
carried the 16p11.2 deletion.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification and validation of deletions at 16p11.2
(a) aCGH data showing the location of the 16p11.2 deletion. The data show the log2
intensity ratio for a deletion carrier compared to an undeleted control sample. Grey bars
connected by a broken line denote the segmental duplication flanking the deletion region.
Vertical bars indicate the positions of the probe pairs used for MLPA validation. Note that
CGH and genotyping array probes targeted against segmental duplications may not
accurately report copy number due to the increased number of homologous sequences in the
diploid state. Genome coordinates are according to the hg18 build of the reference genome.
(b) MLPA validation of 16p11.2 deletions. Representative MLPA results are shown,
illustrating one instance of maternal transmission and two instances of de novo deletions.
Genotyping data excluded the possibility of non-paternity. Full results for MLPA validation
and inheritance analysis are shown in Supplementary Figure S1. Each panel shows the
relative magnitude of the normalised, integrated signal at each probe location, in order of
chromosomal position of the MLPA probe pairs as indicated in (a). Each panel corresponds
to its respective position on the associated pedigree, as shown.
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Figure 2. Dependence of BMI on age in subjects having a deletion at 16p11.2
Data are for all individuals carrying a deletion for whom phenotypic data are available.
Similar data from this study only are shown in Supplementary Figures S2 and S3. Lines
denote the age- and gender-corrected thresholds (solid/broken – male/female) for obesity
and morbid obesity. Symbols are: Square/circle – male/female; black/grey – ascertained/not
ascertained for developmental delay; filled/open – ascertained/not ascertained for obesity;
diamond – first-degree relative of proband; cross – previously published data10-15. The 31
year old male with BMI ~20 kg.m−2 was diabetic based on fasting blood glucose >7 mmol/
L.
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